Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Int J Cancer 2002 Feb;97(5):626-30

Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells. In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP). The exogenous BCRP protein migrated as a 70-kDa protein in SDS-PAGE under reducing condition, but migrated as a 140-kDa complex in the absence of reducing agents. The 140-kDa BCRP complex was heat-stable but dissociated into 70-kDa BCRP with the addition of 2-mercaptoethanol. The 140-kDa BCRP complex was immunoprecipitated with anti-Myc antibody from the lysates of PA317 cells double-transfected with MycBCRP and HABCRP. The 140-kDa complex reacted with anti-HA and anti-BCRP antibodies and after the addition of reducing agents, a 70-kDa protein reacting with anti-Myc, anti-HA and anti-BCRP antibodies was detected. These results clearly indicate that BCRP forms a homodimer bridged by disulfide bonds. To assess the possible dominant-negative inhibition of BCRP drug efflux pump, various mutant BCRP cDNAs were isolated by PCR mutagenesis. First, mutant BCRP cDNAs were introduced to parental PA317 cells and tested for their function as drug-resistance genes. Next, inactive BCRP cDNA clones were introduced to MycBCRP-transfected cells and tested for the ability to lower drug resistance. Among the 8 inactive mutant cDNA clones tested, HABCRP cDNA clone 15 with an amino acid change from Leu to Pro at residue 554 in the fifth transmembrane domain of BCRP partially reversed the drug resistance of MycBCRP-transfected cells. These results suggest that homodimer formation is essential for BCRP drug resistance, implicating this dominant-negative inhibition as a new strategy to circumvent drug resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.10100DOI Listing
February 2002
7 Reads

Publication Analysis

Top Keywords

drug resistance
16
bcrp
14
dominant-negative inhibition
12
140-kda bcrp
8
bcrp complex
8
140-kda complex
8
70-kda protein
8
pa317 cells
8
reducing agents
8
mutant bcrp
8
cdna clones
8
mycbcrp-transfected cells
8
cells tested
8
bcrp cdnas
8
bcrp drug
8
anti-bcrp antibodies
8
anti-ha anti-bcrp
8
resistance protein
8
cancer resistance
8
drug efflux
8

References

(Supplied by CrossRef)

Gottesman et al.
Annu Rev Genet 1995

Chen et al.
Cell 1986

Ueda et al.
J Biol Chem 1987

Pastan et al.
Proc Natl Acad Sci USA 1988

Cole et al.
Science 1992

Doyle et al.
Proc Natl Acad Sci USA 1998

Allikmets et al.
Cancer Res 1998

Miyake et al.
Cancer Res 1999

Litman et al.
J Cell Sci 2000

Allen et al.
Cancer Res 1999

Ross et al.
J Natl Cancer Inst 1999

Similar Publications